Celyad SA Stock News

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innov

How to make money with penny stocks in 2023 The post What Penny Stocks Trends Can Help You Profit in 2023? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Celyad Oncology SA (NASDAQ:CYAD ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sara Zelkovic - Director, Communications and Investor Relations Michel Lussier - Inter

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused o

Celyad is a seemingly neglected immuno-oncology-focused nano-cap, liked by analysts and experts abound, but somehow overlooked by the market. Four months ago, its share price took a dive following a c

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and deve

Celyad Oncology SA (CYAD) CEO Filippo Petti on Q4 2021 Results - Earnings Call Transcript

MONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeri

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused o

The FDA has issued a clinical hold on Celyad Oncology SA''s (NASDAQ: CYAD ) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to insufficient information to assess risk to study subjects. As previously disclosed, the Company … Full story available on Benzinga.com

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endometrial Cancer Karyopharm Therapeutics, Inc. (NASDAQ: KPTI ) said following discussions with the U.S. Food and Drug Administration regarding its previously planned supplemental new drug Application for selinexor in advanced or recurrent endometrial cancer , the regulator conveyed that topline results from the Phase 3 SIENDO study are unlikely to support approval. The regulator said further exploration of patients with advanced or recurrent endometrial cancer with p53 wild-type is warranted. Taking into account, the FDA''s feedback, the company intends to initiate a new study of selinexor in patients with p53 wild-type endometrial cancer and believes top-line data will be available in the first half of 2024. The stock was slumping 26.95% to $7.59 in premarket trading. Finch Pauses Phase 3 Study Of Microbiome Therapeutic CP101 Following FDA''s Clinical Hold Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) announced that it has paused enrollment in PRISM4 Phase 3 clinical trial of CP101 in recurrent C. difficile infection following the receipt of a clinical hold letter from FDA on Feb. 24, requesting additional information about Finch''s SARS-CoV-2 donor screening protocols.

The U.S. Food and Drug Administration placed a clinical hold on Celyad Oncology''s (CYAD) phase 1b trial, dubbed CYAD-101-002 (KEYNOTE-B79), due to insufficient information to assess…

Celyad Oncology SA (NASDAQ: CYAD ) has decided to voluntarily pause the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial, a part of a collaboration with Merck & Co Inc (NYSE: MRK ). The trial is evaluating the company''s CYAD-101 administered concurrently with FOLFOX chemotherapy, … Full story available on Benzinga.com

Celyad Oncology (CYAD) voluntarily paused its CYAD-101-002 (KEYNOTE-B79) phase 1b trial (NCT04991948) in colorectal cancer, after it received reports of two fatalities that presented…